After TURBT, Anlotinib Hydrochloride combined with radiotherapy to preserve bladder for treatment of myometrial invasive bladder cancer

Phase 4

• Conditions: Bladder Cancer

• Registration Number: ITMCTR1900002674
• Lead Sponsor: iuzhou Chinese Medicine Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1, between the ages of 18 and 85, male or female;
2. Clearly diagnosed as myometrial invasive bladder cancer by histopathology and/or cytology;
3. Rejection of chemotherapy after surgery;
4, with measurable lesions (spiral CT scan greater than 10mm, meet the RECIST1.1 standard);
5. The patient has an estimated KPS score of 70 or more;
6. The estimated survival period >=3 months.

Exclusion Criteria

1. End-stage patients cannot tolerate treatment;
2. The assessment of chronic combined basic diseases may interfere with treatment;
3. Combined with severe liver and kidney dysfunction;
4. The tumor has invaded an important blood vessel or a patient who has been judged by the investigator to have major bleeding during the follow-up study;
5. Patients with any signs or history of bleeding physique.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Tumor size;